PainChek (ASX:PCK)- CEO, Philip Daffas
CEO, Philip Daffas
Source: PainChek
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Pain detection app developers PainChek (PCK) has expanded its presence in New Zealand through a partnership with Medi-map
  • The Medi-map platform is the leading medication management software for aged care providers in New Zealand
  • Under the partnership, Medi-map will promote PainChek to their aged care clients andPainChek’s results will also be integrated into the platform
  • The New Zealand market presents a strong market opportunity, with almost 40,000 residents in aged care and 70,000 people living with dementia
  • On market close, PainChek shares fell 4.44 per cent and is trading for 8.6 cents per share

PainChek (PCK) has expanded its presence in New Zealand through a partnership with Medi-map.

The Medi-map platform is the leading medication management software for aged care providers in New Zealand. Its platform manages all aspects of medication, sharing medication charts between the prescriber, pharmacy and care organisations.

Medi-map has around 80 per cent of the New Zealand residential aged care market under contract.

PainChek is the developer of the world’s first smartphone-based pain assessment and monitoring application. The app detects pain in individuals with moderate to severe dementia in aged care facilities and at home.

However, the company is also looking to move to the disability industry, as it recently signed a partnership deal with a disability service provider.

Under the partnership, Medi-map will promote PainChek to their aged care clients. PainChek’s results will also be integrated into the Medi-map platform.

Medi-map CEO, Greg Garratt, is thrilled to partner with PainChek, citing a great working synergy between both companies.

“Combining best in breed pain assessment with real-time medication management is extremely exciting and powerful from a resident outcome’s perspective,” he said.

“Integrating PainChek results into Medi-map will lead to improved resident outcomes and better care. Something both companies are passionate about,” he added.

The New Zealand market presents another market opportunity for PainChek, with almost 40,000 residents in aged care and 70,000 people living with dementia.

PainChek CEO, Philip Daffas, says the companies have the same goal in terms of delivering better consideration within aged care.

“Integrating PainChek pain assessments with the Medi-map medication
system provides carers with the ability to diagnose and treat residents in pain in real-time,” he said.

“This is a great step forward. The collaboration is another example of our digital capability, delivering PainChek to international clients in a cost-effective, integrated way and through a flexible business model built for modern-day healthcare,” he added.

On market close, PainChek shares fell 4.44 per cent and is trading for 8.6 cents per share.

PCK by the numbers
More From The Market Online
The Market Online Video

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Pharmaceutical companies can bring new hope to patients by delivering solutions to unmet medical needs. They…

Althea on a high as it opens cannabis drinks in the US with Flora Growth

Peak Processing has joined forces with Flora Growth to introduce cannabis drinks to the US beverages…

AFT Pharma reports record earnings, boosted sales and significant launches in US

AFT Pharmaceuticals Ltd has reported record earnings for the year ended March 31, as well as…

Pacific Edge revenues up, cash costs down on reorganisation

Pacific Edge Ltd has balanced a drop in cash costs with falls in total cash at…